MedDataX Logo

The Efficacy and Safety of Different Phlebotonic Drugs in Children With Venous Malformations

NCT ID: NCT05113420

Last Updated: 2021-11-09

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-09-17

Study Completion Date

2022-09-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the efficacy and safety of different phlebotonic drugs in children and to assess patient satisfaction after treatment.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug Effect Children, Only Vascular Malformations Surgery

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Per os+topical solution(1)

Detralex

Intervention Type DRUG

Diosmin+ Hesperidin

Per os+topical solution(2)

Detralex

Intervention Type DRUG

Diosmin+ Hesperidin

Troxevasin

Intervention Type DRUG

Troxerutin

Per os only

Detralex

Intervention Type DRUG

Diosmin+ Hesperidin

Topical solution only

Detralex

Intervention Type DRUG

Diosmin+ Hesperidin

Troxevasin

Intervention Type DRUG

Troxerutin

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Detralex

Diosmin+ Hesperidin

Intervention Type DRUG

Troxevasin

Troxerutin

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* venous malformation

Exclusion Criteria

* allergy
Minimum Eligible Age

1 Year

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Center for Vascular Pathology, Moscow

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Ekaterina Listovskaia, MD

Role: STUDY_CHAIR

Vascular Anomalies Center (VAC) "Hemangioma" LLC.

Dmitriy Romanov, MD

Role: STUDY_CHAIR

Vascular Anomalies Center (VAC) "Hemangioma" LLC.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

The Vascular Anomalies Center (VAC) "Hemangioma" LLC

Moscow, , Russia

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Russia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ekaterina Listovskaia

Role: CONTACT

Phone: +79032069027

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ekaterina Listovskaya

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

VAC_VM

Identifier Type: -

Identifier Source: org_study_id